SUPPLEMENT APPROVAL

Mylan Specialty, L.P.
781 Chestnut Ridge Road
Morgantown, West Virginia 26504-4310

Attention: Wayne Talton
Head, Global Regulatory Affairs

Dear Mr. Talton:

Please refer to your supplemental new drug application (sNDA) dated July 31, 2019, received July 31, 2019, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for EpiPen Auto-Injector, EpiPen Jr Auto-Injector (0.3 mg/0.3 mL, 0.15 mg/0.3 mL).

This Prior Approval supplemental new drug application provides for revisions to the Prescribing Information, Patient Information leaflet and Instructions for Use, Trainer Instruction for Use, to include instructions for the disposal of expired auto-injectors and the safety release.

APPROVAL & LABELING

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Information leaflet and Instructions for Use, Trainer Instruction for Use), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As.²

¹ [Link](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm)
² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database [Link](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 019430/S-082**.” Approval of this submission by FDA is not required before the labeling is used.

**REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ji Hyun LaRose, Regulatory Project Manager, at (301) 796-9017.

__________________________

U.S. Food and Drug Administration
Silver Spring, MD 20993
[www.fda.gov](http://www.fda.gov)

Reference ID: 4555155
Sincerely,

{See appended electronic signature page}

Sally Seymour, MD
Director
Division of Pulmonary, Allergy, and Rheumatology
Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
  - Prescribing Information
  - Patient Information leaflet and Instruction for Use
  - Trainer Instructions for Use
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

SALLY M SEYMOUR
01/31/2020 04:18:00 PM